Table 1 Baseline demographic and clinical characteristics in MVI− and MVI + groups

Age (years)

54.0 (42.0, 62.0)

54.0 (48.0, 64.0)

51.0 (40.5, 61.5)

Gender

 Male

31 (88.6%)

14 (82.4%)

17 (94.4%)

 Female

4 (11.4%)

3 (17.6%)

1 (5.6%)

HBsAg

 Negative

3 (8.6%)

1 (5.9%)

2 (11.1%)

 Positive

32 (91.4%)

16 (94.1%)

16 (88.9%)

AFP (ng/mL)

  ≥ 400

10 (28.6%)

16 (94.1%)

9 (50.0%)

  < 400

25 (71.4%)

1 (5.9%)

9 (50.0%)

Tumor size (cm)

4.0 (3.1, 5.1)

3.5 (3.1, 5.1)

4.0 (3.0, 5.5)

Tumor number

 Solitary

34 (97.1%)

16 (94.1%)

18 (100.0%)

 Multiple

1 (2.9%)

1 (5.9%)

0 (0.0%)

Child–Pugh class

 A

33 (94.3%)

16 (94.1%)

17 (94.4%)

 B

2 (5.7%)

1 (5.9%)

1 (5.6%)

Liver cirrhosis

 Absence

12 (34.3%)

6 (35.3%)

6 (33.3%)

 Presence

23 (65.7%)

11 (64.7%)

12 (66.7%)

BCLC stage

 0–A

26 (74.3%)

14 (82.4%)

12 (66.7%)

 B–C

9 (25.7%)

3 (17.6%)

6 (33.3%)

TNM stage

 0–I

30 (85.7%)

16 (94.1%)

14 (77.8%)

 II–III

5 (14.3%)

1 (5.9%)

4 (22.2%)

Imaging tumor thrombus

 Absence

30 (85.7%)

17 (100.0%)

13 (72.2%)

 Presence

5 (14.3%)

0 (0.0%)

5 (27.8%)

Tumor necrosis

 Absence

26 (74.3%)

15 (88.2%)

11 (61.1%)

 Presence

9 (25.7%)

2 (11.8%)

7 (38.9%)

Tumor differentiation

 Well or moderate

30 (85.7%)

15 (88.2%)

15 (83.3%)

 Poor

5 (14.3%)

2 (11.8%)

3 (16.7%)

Ascites

 Absence

34 (97.1%)

17 (100.0%)

17 (94.4%)

 Presence

1 (2.9%)

0 (0.0%)

1 (5.6%)

ALB (g/L)

40.2 (37.5, 41.6)

40.4 (38.4, 41.8)

39.5 (36.8, 41.3)

TBIL (μmol/L)

14.4 (11.4, 21.1)

12.7 (11.3, 19.4)

16.1 (11.8, 22.7)

ALT (U/L)

33.0 (25.0, 50.0)

33.0 (25.0, 50.0)

33.0 (26.0, 46.5)

AST (U/L)

33.0 (25.0, 40.5)

34.0 (26.0, 41.0)

32.0 (25.3, 40.0)

PT (s)

12.1 (11.5, 13.1)

12.1 (11.5, 12.3)

12.1 (11.5, 13.3)

PLT (10⁹/L)

164.0 (111.0, 206.0)

165.0 (150.0, 200.0)

154.5 (104.25, 203.0)